USPTO 2015–2025 USPTO PatentsView US Corporation

Arkis Biosciences Inc.

USPTO PatentsView assignee record - 11 granted patents across 2 technology areas, recorded in grant years 2016–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

RSS updates for this company

The verdict

According to USPTO PatentsView, Arkis ranks #23,900 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 2 technology areas.

#23,900
of 49,997 US assignees by volume
8th percentile
by Innovation Score (21.2/100)
12.7
avg claims per patent
-90%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R23900 · US Corporation #23,900 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MICRO 11 grants
  • MID-PACK #23,900/49,997
  • PHOTO-FINISH Arcimoto
  • CPC-NARROW A61B · 2 areas
  • INNOV-THIN 21.2/100
  • CLAIMS-RICH 12.7 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DROP -90% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Arcimoto, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Arkis’s 21.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Arkis

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Arkis's Innovation Score is 21.2/100 (8th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Arkis?

Each dot is one of Arkis’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Arkis’s own 12.7 claims/patent is at or below the 15.0 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Arkis vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 10.910.91111.1 0102030 Granted patents (volume) Avg claims / patent Arcimoto, Inc. - 11, 15ArcimotoArgen-x N.V. - 11, 22.55Argen-xAria Solutions, Inc. - 11, 6.91Aria SolutionsArjowiggins Security - 11, 27Arjowiggins Secur…ARx, LLC - 11, 20.64ArxAscentia Imaging, Inc. - 11, 14.55Ascentia ImagingAsia Satellite Telecommunications Company Limited - 11, 20.64Asia Satellite Te…ASO LLC - 11, 2.45ASOArkis Biosciences Inc. - 11, 12.73Arkis Biosciences
Arkis vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Arkis's grants concentrate

Arkis Biosciences Inc. is a focused PatentsView assignee: 2 CPC subclasses with 54.5% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2017 (3 grants) versus a trough of 1 in 2020. By volume, Arkis sits between Arcimoto, Inc. and ASO LLC.

Who files at Arkis's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Arkis holds 11 patents at rank #23,831, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Arkis

By rank, the assignees closest to #23,831 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Arkis's primary technology class.

Arkis's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

21 8th percentile higher than 8% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 20162017201820192020 1
USPTO utility patent grants by year · 2016–2020

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
Arkis Biosciences Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 2 18.2%
2017 3 27.3%
2018 3 27.3%
2019 2 18.2%
2020 1 9.1%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Arkis Biosciences Inc.'s patent record in context - here's where to go next.

  • Arkis Biosciences Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 54.5% of its portfolio - see every assignee active in that class. Explore A61B
  • Ranked #23,900 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Arkis Biosciences Inc. against Arcimoto, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 21.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.